PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load

Overview

The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by PACAP compared to patients with few genetic loci associated with migraine (low genetic load).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: November 2014

Detailed Description

Migraine is a very prevalent neurological disorder with a strong genetic factor. The common forms of migraine have a multifactorial and polygenic pattern of inheritance and genetics research is crucial for a deeper understanding of migraine mechanisms. Recently, 12 genetic loci have been identified to be associated with migraine with (MA) and without aura (MA) in four large genome-wide association studies (GWAS). The functional consequences of this genetic variant in humans are yet unknown. PACAP is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. PACAP can induce migraine attacks in MO patients via an adenosine monophosphate (cAMP) dependent pathway. Also, a recent study has showed that intracellular accumulation of cAMP is crucial for the induction of migraine attacks. The phenotype of the migraine inducing effects of PACAP might therefore be linked to some of the 12 genetic susceptibility loci that have been identified.

Interventions

  • Drug: PACAP
    • Pituitary adenylate cyclase-activating polypeptide (PACAP)

Arms, Groups and Cohorts

  • Active Comparator: Migraine patients with high genetic load
    • PACAP intravenous infusion 1.5 microgram/min for 20 min
  • Active Comparator: Migraine patients with low genetic load
    • PACAP intravenous infusion 1.5 microgram/min for 20 min

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of migraine attacks induced by PACAP in patients with high and low genetic load.
    • Time Frame: Change from baseline in headache intensity at 12 hours after the start of infusion of PACAP
    • The difference in incidence of migraine-like attacks after PACAP between patients with and without high genetic load and patients with low genetic load using verbal rating scale (VRS).

Secondary Measures

  • Incidence of headache induced by PACAP in patients with high and low genetic load.
    • Time Frame: Change from baseline in headache intensity at 12 hours after the start of infusion of PACAP
    • The difference in area under the curve (AUC) for headache intensity scores (0-12 hours) after infusion of PACAP

Participating in This Clinical Trial

Inclusion Criteria

  • Migraine without aura patients genotyped for the 12 newly idetified gene variants associated with migraine. Exclusion Criteria:

  • Other primary headache – A history of cerebrovascular disease and other CNS- disease – A history suggesting ischaemic heart disease – Serious somatic and mental disease – Hypo- or hypertension – Abuse of alcohol or medicine (opioid analgesics). – Pregnant or breastfeeding women.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Danish Headache Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Song Guo, MD – Danish Headache Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.